Background
==========

Chronic lymphocytic leukemia (CLL) is a heterogeneous disease with variable clinical course characterized by a monoclonal progressive accumulation of mature CD5+ B-lymphocytes avoiding apoptosis. Some patients with an indolent disease need no or little treatment while others have a more adverse disease at diagnosis. No common genetic lesion, which causes the disease, has been found \[[@B1]\], but recurrent mutations in CLL involve *TP53* and *ATM*, and novel mutations in the *NOTCH1, SF3B1, MYD88, BIRC3* and *FBXW7* genes have been identified through next generation sequencing \[[@B2]\]. The CLL cases may be divided in two major groups regarding to mutated (M) or unmutated (UM) immunoglobulin heavy chain variable region gene (IGHV) where patients with an unmutated IGHV clone have a more adverse prognosis than patients with mutated IGHV gene \[[@B3],[@B4]\]. By the means of FISH analysis, different chromosomal aberrations as deletion in 11q, 13q, 17p or trisomy 12 are found in about 80% of tumor cells in the CLL-patients \[[@B5]\].

Recently, *NOTCH1* mutations were found to be predictor of poor prognosis in CLL \[[@B6]-[@B11]\]. Furthermore a study of Rosati et al. \[[@B12]\] showed that NOTCH1 and NOTCH2, together with their ligands Jagged1 --and 2 are constitutively activated in B-CLL cells but not in normal B cells, suggesting that NOTCH signaling is involved in survival and resistance to apoptosis in CLL.

The NOTCH receptor is a membrane bound protein that consists of an extracellular, transmembrane and intracellular domain that can be released upon ligand interaction and transactivate target genes. The NOTCH signal pathway is activated by a ligand on a neighboring cell and plays an essential role in controlling proliferation, differentiation and survival. Following the receptor-ligand binding, the NOTCH receptor first undergoes a S2 proteolytic cleavage by ADAM proteinase in the extracellular domain, which then is followed by a S3 cleavage by a γ-secretase complex in the transmembrane domain releasing the intracellular NOTCH domain that translocates to the nucleus where it interacts with a transcription complex and acts as a transcriptional activator for multiple target genes \[[@B13]\]. The C-terminal part of the intracellular domain consists of a PEST region that is important for proteasomal degradation of the NOTCH receptor by binding to FBXW7, an E3 ubiquitin ligase, to limit duration of the NOTCH activity. A CT deletion in the C-terminal region results in removal of the PEST domain, a truncated NOTCH protein, and impaired NOTCH degradation and constitutive transcriptional activation of NOTCH target genes in CLL \[[@B7],[@B14]\].

In the present study we have screened for mutations in different parts of both the *NOTCH1* and *NOTCH2* gene in a cohort of 209 CLL-patients. There is a high structural similarity between *NOTCH1* and *NOTCH2* genes and recent *NOTCH2* gain-of-function mutations are found in B-cell lymphomas \[[@B15]\]. Further, as NOTCH2 is involved in overexpression of CD23, one of the hallmarks of CLL \[[@B16]\], it prompted us to screen both the *NOTCH1* and *NOTCH2* genes for genetic alterations. Mutations were only found in the PEST region in the *NOTCH1* gene in our cohort and emerged as an independent factor of poor overall survival and disease stage, in addition to *TP53* mutations and IGHV gene status.

Methods
=======

Patients
--------

In this study, peripheral blood from 209 CLL patients (145 men and 64 women) was collected between 1996 and 2006 at the Department of Hematology, Linköping University Hospital. Mononuclear cells were isolated by Ficoll-Paque gradient centrifugation and genomic DNA was extracted by proteinase K digestion and stored frozen until used as earlier described \[[@B17]\]. The samples were collected either at the time of diagnosis or prior to the first treatment. For all patients, follow-up data were available, and for 106 live patients the median follow-up time was 6.8 years (range 1.6-14.9 years). The median age at diagnosis was 62.5 years (range 38.3-87.0 years). The immunophenotype and the Binet staging system were according to the IWCLL guidelines \[[@B18]\]. The immunoglobulin heavy chain variable region genes (IGHV) and *TP53* gene status were analysed and reported in an earlier study \[[@B17]\]. Informed consent was obtained from the patients and the study was approved by the regional ethical committee (Dnr 02--459) in Linköping and conducted in accordance with the ethical guidelines of the Helsinki Declaration.

*NOTCH* mutation status detection
---------------------------------

The *NOTCH1* mutations status were analyzed for the extracellular region (exon 6, 7, 8, 11, 12 and 13), the heterodimerisation domain (exon 26, 27) and the PEST region (exon 34) and the *NOTCH2* was only analyzed for mutations in the heterodimerisation and the PEST domains by PCR amplification followed by single strand conformation analysis (SSCA) according to the original protocol \[[@B19]\] and direct dideoxy sequencing to determine the exact nucleotide change and compared to corresponding *NOTCH1* and *NOTCH2* germline sequence (NM_017617.3 and NM_024408.3 respectively). Primer sequences are shown in Table [1](#T1){ref-type="table"}.

###### 

Primer sequences

   **Gene-exon-segment**   **Application**  **Forward primer**      **Reverse primer**       **Product size/bp**   **T**~**A**~**/°C**
  ----------------------- ----------------- ----------------------- ------------------------ --------------------- ---------------------
       Notch1- 26-a           PCR/SSCA      AGCCCCCTGTACGACCAGTA    CTTGCGCAGCTCCTCCTC       283                   63.5
       Notch1- 26-b           PCR/SSCA      ACACGGCCAGCAGATGAT      GAGAGTTGCGGGGATTGAC      231                   57.1
        Notch1- 27            PCR/SSCA      GTGGCGTCATGGGCCTCA      TAGCAACTGGCACAAACAGC     342                   63.2
        Notch1- 34a           PCR/SSCA      AACCACCTGCCTGGGATG      CGCATTGACCATTCAAACTG     232                   57.1
        Notch1- 34b           PCR/SSCA      GGGCCCTGAATTTCACTGT     AGGCCCTGGTAGCTCATCAT     229                   60
        Notch1- 34c           PCR/SSCA      GCTGCACAGTAGCCTTGCT     CTGAGCTCACGCCAAGGT       224                   58
        Notch1- 34d           PCR/SSCA      ACATCCAGCAGCAGCAAAG     GTGGGACCAGCGAGGATG       222                   58
        Notch1- 34e           PCR/SSCA      CACTATTCTGCCCCAGGAGA    CAGTCGGAGACGTTGGAATG     234                   58
        Notch1- 34f           PCR/SSCA      ACAGCTACTCCTCGCCTGTG    AAGGCTTGGGAAAGGAAGC      248                   58
         Notch1-6             PCR/SSCA      GCAGCTGCCCGGGGCCGACA    TCAGGCCTGGCCCATGTGA      330                   62
         Notch1-7             PCR/SSCA      ATGCCTGGCCAGGGGCCGT     TCGACTTCTCATCGGTTCT      273                   58
         Notch1-8             PCR/SSCA      CCGATGGGGGTGGTGTGCAGT   TGCCCAGCCTCGACTCGGTT     331                   63
         Notch1-11            PCR/SSCA      AGTCCTAAGTCTTCCTGTGCC   AGGCCCGCCCTGCCCACT       325                   65
         Notch1-12            PCR/SSCA      AGGACTGACCGACACGTG      TCTGAGCACAGTGCAGTCA      183                   53
         Notch1-13            PCR/SSCA      TGGGCGCTGGGCCTCGGA      ACTGATGTGTCCCCATGA       268                   54
   **Gene-exon-segment**   **Application**  **Forward primer**      **Reverse primer**       **Product size/bp**   **T**~**A**~**/°C**
       Notch2- 26-1           PCR/SSCA      TTCTCTGCTTCCCCTTACCT    TTAATGCGCAGGTTGGTGT      250                   54.1
       Notch2- 26-2           PCR/SSCA      TGGTATTGATGCCACCTGAA    GCCTTGAAGTTCAGAAACCAA    240                   54.1
        Notch2- 27            PCR/SSCA      TACCCCCATCTCTCCTCCTC    AATTGTTCCCCCAATTGACA     250                   55.2
       Notch2- 34-1           PCR/SSCA      TCCCCTGTTGATTCCCTAGA    CACAATGTGGTGGTGGGATA     249                   55.2
       Notch2- 34-2           PCR/SSCA      GCACTGTGCTTCCCTCAGT     CTGCCTTTAGGGATGAGCTG     298                   55.2
       Notch2- 34-3           PCR/SSCA      ACCCATCCTGGCATAGCTC     TAGGCTGGGAGAATGGTCTG     287                   55.2
       Notch2- 34-4           PCR/SSCA      TTTGCCCAGTGTGGCTTT      GGTGATGAACTTGACCACTG     249                   57.1
       Notch2- 34-5           PCR/SSCA      ACACCCAGTCACAGTGGTCA    TGTCTCTACACTGGAGGTGGAC   242                   61.6

*TP53* and IGHV gene status detection
-------------------------------------

*TP53* gene mutation analysis was performed for exons 5--8 (the DNA binding domains) by the PCR-single strand conformation analysis (SSCA) technique and samples displaying mobility shifts were sequenced with the dideoxy termination method to confirm the nucleotide changes.

The IGHV gene mutational status was performed by PCR amplification on genomic DNA by using specific VH/JH primers \[[@B20]\], followed by DNA sequencing of both forward and reverse strands. To determine the IGHV gene identity the sequences were aligned by using the IMGT/V-QUEST database (<http://imgt.org>), ≥ 98% identity to the corresponding germline sequence was considered as an unmutated IGHV gene.

Statistical analysis
--------------------

Kaplan-Meier curves were used to show the overall survival and the log-rank test was used to compare the survival between the groups. To calculate hazard ratios (HR) the Cox proportional hazard model (Cox-regression) was used. For all statistical analyses Stata v12.1 was used (StataCorp LP, College Station, TX, USA). P-values less than 0.05 were considered significant. Overall survival was measured from date of diagnosis until the last follow-up or death.

Results and discussion
======================

*NOTCH1* heterozygous mutations in the PEST domain occurred in a frequency of 14 out of 209 patients (6.7%) in our study. Thirteen of the mutations correspond to a 2-bp frameshift deletion, c.7541_7542delCT and one is a novel GT deletion at c.6988_6989delGT, both generating frameshift mutations, with subsequent stopcodon and truncated proteins eliminating the PEST domain. The Kaplan-Meier curve for the CLL-patients with *NOTCH1* mutations revealed a shorter overall survival (OS) compared to *NOTCH1* wildtype patients (p = 0.049) (Figure [1](#F1){ref-type="fig"}). Clinical and biological characteristics of the CLL patients in relation to the *NOTCH1* status are summarized in Table [2](#T2){ref-type="table"}. Our study showed a similarity to other CLL studies, which have reported *NOTCH1* PEST domain mutations in 4.7% - 12.2% \[[@B6]-[@B11]\].

![**Kaplan-Meier survival curves displaying a significant difference between patients with*NOTCH1*mutation (n = 14) and*NOTCH1*wildtype (n = 195) (p = 0.049).**](1471-2407-13-274-1){#F1}

###### 

Clinical and biological characteristics of the 209 CLL-patients

                                  ***NOTCH1***                        
  ------------------------ ----- -------------- ----- ---- ---- ----- ------
  **Number of patients**    209                  195        14           
  **Sex**                                                              0.67
    male                    145        69        136   70   9    64      
    female                  64         31        59    30   5    36      
  **Binet stage**                                                      0.11
    A                       101        48        98    50   3    21      
    B/C                     91         44        82    42   9    64      
    Not determined          17         8         15    8    2    14      
  **Treatment**                                                        0.22
    yes                     182        87        168   86   14   100     
    no                      20         10        20    10   0     0      
    Not determined           7         3          7    4    0     0      
  **IGHV status**                                                      0.22
    Mutated                 64         31        61    31   3    21      
    Unmutated               123        59        113   58   10   71      
    Not determined          22         10        21    11   1     7      
  ***TP 53*status**                                                    0.88
    wild-type               196        94        183   94   13   93      
    mutated                 13         6         12    6    1     7      

T cell acute lymphoblastic leukemia (T-ALL) display high frequency of activating *NOTCH1* mutations including the extracellular heterodimerisation domain, in addition to elimination C-terminal PEST region mutations \[[@B21]\]. Studies in head and neck cancer have also identified mutations in the extracellular epiderminal growth factor repeat domain in the *NOTCH1* gene \[[@B22]\]. These studies prompted us to screen for mutations in those parts of the *NOTCH1* gene, but no mutations could be detected. NOTCH2 has a role in marginal zone B cell fate decision, similar to the critical role for NOTCH1 in determing the T-cell fate \[[@B13]\]. *NOTCH2* mutations are found in the C-terminal part close to the PEST region in splenic marginal zone lymphoma \[[@B23],[@B24]\], but we did not find any mutations in the PEST region or heterodimerisation domain of the *NOTCH2* gene in our cohort.

Mutations in the *TP53* gene are associated with poor prognosis in CLL \[[@B25]\]. Mutations in the *NOTCH1* gene are almost mutually exclusive with mutations in the *TP53* gene with or without 17p or 11q deletions, only one sample harbored mutations in both *NOTCH1* and *TP53*. Combined, *NOTCH1* (6.7%) and *TP53* (6.2%) mutations represent 12.9% of the patients in this cohort and indicated a significant worse survival as compared to wildtype *NOTCH1* and *TP53* (Log rank analysis, p = 0.002) (Figure [2](#F2){ref-type="fig"}). *NOTCH1* mutations may appear together with trisomy 12 \[[@B26],[@B27]\], and in our cohort, trisomy 12 was found in 15/152 patients by BAC (bacterial artificial chromosome) microarray analysis and two of these carried *NOTCH1* mutation; this association was not significant (p = 0.56). By univariate analysis, the HR for death increased to 2.27 (1.32-3.91; 95% confidence interval) for tumors mutated in *NOTCH1* or *TP53* compared to *NOTCH1* and *TP53* wildtype tumors (p = 0.003) (Table [3](#T3){ref-type="table"}). At the molecular level there seems to be an intriguing and complex link between p53 and NOTCH1. P53 induce NOTCH1 expression and seems to initiate an anti-apoptotic feedback mechanism with subsequent increased cell survival that may limit p53 promoting therapy with e.g. nutlins \[[@B28],[@B29]\]. NOTCH signaling blockade by γ-secretase inhibitors to stimulate apoptosis may be considered to be of therapeutic value at least for wt p53 CLL patients \[[@B28]\].

![**A significant difference in overall survival between patients with*NOTCH1*or*TP53*mutations (n = 26) and CLL with non-mutated*NOTCH1*and*TP53*(n = 183*)*(p = 0.002).**](1471-2407-13-274-2){#F2}

###### 

Analysis for overall survival

                                 **N**   **HR**   **95% CI**   ***P***   **HR**^**1**^   **95%CI**   ***P***
  ------------------------------ ------- -------- ------------ --------- --------------- ----------- ---------
  Wildtype *NOTCH1* and *TP53*   183     1                               1                            
  Mutated *NOTCH1* or *TP53*     26      2.27     1.32-3.91    0.003     2.16            1.25-3.72   0.006
  Wildtype *NOTCH1*              195     1                               1                            
  Mutated *NOTCH1*               14      2.04     0.98-4.25    0.056     1.80            0.86-3.76   0.12
  Wildtype *TP53*                196     1                               1                            
  Mutated *TP53*                 13      2.54     1.17-5.54    0.019     2.54            1.17-5.53   0.002

*HR*, hazard ratio; *CI*, confidence interval.

^1^Adjusted for age and sex.

Among CLL patients with a mutated *NOTCH1* gene 10/14 (71%) had an unmutated IGHV gene in contrast to 113/195 (58%) with a wildtype *NOTCH1* gene, a difference that did not reach statistical significance (p = 0.22) (Figure [3](#F3){ref-type="fig"} and Table [2](#T2){ref-type="table"}). CLL with *NOTCH1* mutations seemed to be more progressive, with a high frequency of unmutated IGHV gene and advanced Binet stages, indicating a more aggressive disease course.

![**Distribution of*NOTCH1*mutations among IGHV gene status and*TP53*gene status.** Ten of fourteen cases with mutated *NOTCH1* gene are found in the unmutated IGHV gene group and only one patient has both *NOTCH1* mutation and *TP53* mutation.](1471-2407-13-274-3){#F3}

Five patients in this cohort had *NOTCH1* mutation at the time of diagnosis. For these patients the median time to first treatment was 101 days (range 21 to 145 days). For the whole group the median time from diagnosis to the first treatment was 438 days (range 0--6021 days). Further and expected, all patients with *NOTCH1* mutations identified at diagnosis had the more advanced Binet stages B and C, a tendency that due to few observations did not reach significance (p = 0.11) (Table [2](#T2){ref-type="table"}). The frequency of *NOTCH1* mutations is also reported to be significantly higher in Richter syndrome, i.e., a progression of CLL into diffuse large lymphoma with often dismal outcome \[[@B8],[@B30]\], however our cohort contained no information on the prevalence of Richter syndrome.

It is now recommended to perform *TP53* mutation analysis in patients with CLL as *TP53* mutations occur in about 5% of cases in absence of 17p deletion and represent an independent prognostic factor associated with worse outcome \[[@B31]\]. CLL patients with 17p deletion and/or *TP53* mutations are strongly associated with refractory disease, and also activated *NOTCH1* mutations were recently suggested to cause refractoriness to fludarabine \[[@B8],[@B9],[@B32]\].

Conclusions
===========

Our study confirms other recent reports that *NOTCH1* mutation eliminating the PEST domain, has a prognostic value as a novel risk marker in CLL similar to *TP53* mutations. Thus both *NOTCH1* and *TP53* mutation may be an indication for earlier and more active treatment or as an indicator for transplantation therapy.
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